Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development

NEW YORK, Jan. 9, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development

http://www.reportlinker.com/p087184/Stem-Cells-Worldwide-Markets-for-Transplantation-Cord-Blood-Banking-and-Drug-Development.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells also have value as a research tool, as their in vitro study would allow scientists to learn more about the function of various organs and the development of particular diseases; stem cells may also eventually permit drug developers to test emerging therapies on diseased cells.

For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the pharmaceutical market. New scientific developments and recent changes in the U.S. Federal government's policy towards stem cells have made this potential more relevant. Kalorama Information has tackled the question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst Alison Sahoo has built models to determine the best, moderate and worst case scenarios for the three key markets for stem cells:

  • Stem Cells in Drug Development
  • Stem Cells in Cord Blood Banking
  • Stem Cell Therapeutics

Stem cell therapeutics potentials are provided, broken down by disease:

  • Cardiovascular disease
  • Lung disease
  • Tooth disease
  • Arthritis
  • Wrinkles/aging skin
  • Incontinence
  • Osteoporosis
  • Diabetes
  • Cancer
  • Bladder disease
  • Infertility
  • Orthopedics
  • Alzheimer's disease
  • Burns (severe)
  • Lupus
  • Parkinson's disease
  • Liver failure
  • Multiple sclerosis
  • Critical limb ischemia
  • Intestinal disease
  • Sickle cell disease
  • Multiple myeloma
  • NH Lymphoma
  • Leukemia

The following trends are discussed in this report:

  • Ethical Questions
  • U.S. – State and Federal Initiatives
  • Research Funding
  • Cord Blood Initiatives
  • International Initiatives
  • Stem Cell Patents
  • Other Healthcare Regulations

CHAPTER ONE: EXECUTIVE SUMMARY

Scope and Methodolgy

Introduction

Current Stem Cell Therapies

Developmental Stem Cell Therapies

Issues In Stem Cell Research

Stem Cell Forecasts

CHAPTER TWO: INTRODUCTION

The Promise of Stem Cells In Medical Treatment

Types of Stem Cells

Embryonic Stem Cells

Adult Stem Cells

Cord Blood Stem Cells

Stem Cell Harvesting

Embryonic Stem Cells

Therapeutic Cloning

Unfertilized Eggs

Adult Stem Cells

Leukapheresis

Peripheral Blood

Cord Blood Stem Cells

Transplantation Approaches

Autologous Transplantation

Allogenic Transplantation

Transplantation Procedures

Cancerous Stem Cells

Other Harmful Stem Cells

Stem Cells in Drug Development

Stem Cell Therapeutics

Stem Cells Targeting Drugs

Stem Cell Generated Organs

CHAPTER THREE: CURRENT STEM CELL THERAPIES

Cancer

Leukemia

Gene Therapy

Multiple Myeloma

Non-Hodgkin's Lymphoma

Non Cancerous Diseases

Aplastic anemia

Immunodeficiency

Lupus

Sickle Cell Disease

Other Conditions

CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES

Alzheimer's Disease

Arthritis

Bladder Disease

Burns

Cancer

Cardiovascular Conditions

Critical Limb Ischemia

Diabestes

Esophagal Disease

Incontinence

Infertility

Intestinal Disease

Liver Failure

Lung Disease

Multiple Sclerosis

Orthopedics

Osteoporosis

Parkinson's Disease

Sickle Cell Disease

Tooth Disease

Wrinkles/Aging Skin

CHAPTER FIVE: STEM CELL FORECASTS

Best Case

Stem Cell Therapeutics

Umbilical Cord Blood Banking

Fees Related to Drug Development

Most Likely Case

Stem Cell Therapeutics

Umbilical Cord Blood Banking

Fees Related to Drug Development

Worst Case

Stem Cell Therapeutics

Umbilical Cord Blood Banking

Fees Related to Drug Development

CHAPTER SIX: ISSUES IN STEM CELL RESEARCH

Ethical Questions

U.S. - State and Federal Initiatives

Research Funding

Federal Funding

State Funding

Cord Blood Initiatives

International Initiatives

Stem Cell Patents

Other Healthcare Regulations

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1 Total Market for Stem Cell Technologies in $ Millions, 2010 - 2020

Table 1-2 Stem Cell Therapeutics Market in $ Millions, 2010 - 2020

Table 1-3 Total Market for Cord Blood Banking Fees in $ Millions, 2010 - 2020

Table 1-4 Total Market for Stem Cell Drug Development Technologies in $ Millions, 2010 - 2020

Figure 1-1 Total Market for Stem Cells - Most Likely Case in $ Millions, 2010 - 2020

CHAPTER TWO: INTRODUCTION

Table 2-1 Established and Emerging Artificial Organ Products by Market Segment, 2010

CHAPTER THREE: CURRENT STEM CELL THERAPIES

Table 3-1 Types of Leukemia, 2011

CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES

Table 4-1 Global Disease Populations Addressed by Potential Stem Cell Therapies, 2011

Table 4-2 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020

Table 4-3 Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2010 and 2020

Table 4-4 Features and Types of Urinary Incontinence, 2011

Table 4-5 Types and Causes of Male Infertility, 2011

Table 4-6 Common Diseases of the Lungs, 2011

CHAPTER FIVE: STEM CELL FORECASTS

Table 5-1 Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2011

Table 5-2 Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020

Table 5-3 Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 - 2020

Table 5-4 131 Best Case: Cord Blood Banking Revenues in $ Millions, 2007 - 2020

Table 5-5 Best Case: Stem Cell-Based Drug Development Technology Fees, 2010 - 2020

Table 5-6 Best Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2010 - 2020

Table 5-7 Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020

Table 5-8 Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 - 2020

Table 5-9 Most Likely Case: Cord Blood Banking Revenues in $ Millions, 2010 - 2020

Table 5-10 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010 - 2020

Table 5-11 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2010 - 2020

Table 5-12 Worst Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 - 2020

Table 5-13 Worst Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 - 2020

Table 5-14 Worst Case: Cord Blood Banking Revenues in $ Millions, 2010-2020

Table 5-15 Worst Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010-2020

Table 5-16 Worst Case: Stem Cell-Based Drug Development Technology Fees in $ Millions 2010-2020

CHAPTER SIX: ISSUES IN STEM CELL RESEARCH

Table 6-1 NIH Funding for Stem Cell Research, 2002 - 2010 in $ Million

Table 6-2 U.S. State Embryonic & Fetal Research Laws

Table 6-3 Positions on Human ES Cell Research by Country, 2011

Table 6-4 EU Laws on hESC Research by Country

To order this report:Blood Supply, Tissue Banking and Transplantation Industry: Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug DevelopmentMore  Market Research ReportCheck our  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.